Search

Your search keyword '"Greco F"' showing total 4,095 results
Start Over Author "Greco F"
4,095 results on '"Greco F"'

2. The language and social behavior of innovators

Author

Colladon, A. Fronzetti, Toschi, L., Ughetto, E., and Greco, F.

Subjects
Computer Science - Computation and Language, Computer Science - Social and Information Networks, Physics - Physics and Society, I.2.7, J.4, H.4.0
Abstract

Innovators are creative people who can conjure the ground-breaking ideas that represent the main engine of innovative organizations. Past research has extensively investigated who innovators are and how they behave in work-related activities. In this paper, we suggest that it is necessary to analyze how innovators behave in other contexts, such as in informal communication spaces, where knowledge is shared without formal structure, rules, and work obligations. Drawing on communication and network theory, we analyze about 38,000 posts available in the intranet forum of a large multinational company. From this, we explain how innovators differ from other employees in terms of social network behavior and language characteristics. Through text mining, we find that innovators write more, use a more complex language, introduce new concepts/ideas, and use positive but factual-based language. Understanding how innovators behave and communicate can support the decision-making processes of managers who want to foster innovation.

Published
2022
Full Text
View/download PDF

5. Seroprotection against tetanus in the Italian general population

Author

Bagordo, Francesco, Grassi, Tiziana, Rota, Maria Cristina, Castiglia, Paolo, Baldovin, Tatjana, Della Polla, Giorgia, Panico, Alessandra, Ogliastro, Matilde, Marchi, Serena, Vicentini, Costanza, Immordino, Palmira, Savio, Marta, Gabutti, Giovanni, Bordino, V., Garlasco, J., Memoli, G., Giandomenico, A., Greco, F., Manini, I., Montomoli, E., Trombetta, CM., Baldo, V., De Fino, M., Marandola, M., Giberti, I., Orsi, A., Barrocci, S., La Porta, R., Arghittu, A., Dettori, M., Boni, M., Ghisellini, S., Maida, CM., Tramuto, F., Vitale, F., Gamper, A., Robatscher, E., Guido, M., Idolo, A., Angelillo, IF., and Napolitano, F.

Published
2024
Full Text
View/download PDF

6. MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy

Author

Pignata, S., Califano, D., Lorusso, D., Arenare, L., Bartoletti, M., De Giorgi, U., Andreetta, C., Pisano, C., Scambia, G., Lombardi, D., Farolfi, A., Cinieri, S., Passarelli, A., Salutari, V., De Angelis, C., Mignogna, C., Priolo, D., Capoluongo, E.D., Tamberi, S., Scaglione, G.L., Arcangeli, V., De Cecio, R., Scognamiglio, G., Greco, F., Spina, A., Turinetto, M., Russo, D., Carbone, V., Casartelli, C., Schettino, C., and Perrone, F.

Published
2024
Full Text
View/download PDF

9. High-order maximum-entropy collocation methods

Author

Greco, F. and Arroyo, M.

Subjects
Computer Science - Computational Engineering, Finance, and Science, Mathematics - Analysis of PDEs, Mathematics - Numerical Analysis
Abstract

This paper considers the approximation of partial differential equations with a point collocation framework based on high-order local maximum-entropy schemes (HOLMES). In this approach, smooth basis functions are computed through an optimization procedure and the strong form of the problem is directly imposed at the collocation points, reducing significantly the computational times with respect to the Galerkin formulation. Furthermore, such a method is truly meshless, since no background integration grids are necessary. The validity of the proposed methodology is verified with supportive numerical examples, where the expected convergence rates are obtained. This includes the approximation of PDEs on domains bounded by implicit and explicit (NURBS) curves, illustrating a direct integration between the geometric modeling and the numerical analysis.

Published
2020
Full Text
View/download PDF

10. Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA -Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial

Author

Lorusso, D, Raspagliesi, F, Ronzulli, D, Valabrega, G, Colombo, N, Pisano, C, Cassani, C, Tognon, G, Tamberi, S, Mangili, G, Mammoliti, S, De Giorgi, U, Greco, F, Mosconi, A, Breda, E, Artioli, G, Andreetta, C, Casanova, C, Ceccherini, R, Frassoldati, A, Salutari, V, Giolitto, S, Scambia, G, Lorusso D., Raspagliesi F., Ronzulli D., Valabrega G., Colombo N., Pisano C., Cassani C., Tognon G., Tamberi S., Mangili G., Mammoliti S., De Giorgi U., Greco F., Mosconi A. M., Breda E., Artioli G., Andreetta C., Casanova C., Ceccherini R., Frassoldati A., Salutari V., Giolitto S., Scambia G., Lorusso, D, Raspagliesi, F, Ronzulli, D, Valabrega, G, Colombo, N, Pisano, C, Cassani, C, Tognon, G, Tamberi, S, Mangili, G, Mammoliti, S, De Giorgi, U, Greco, F, Mosconi, A, Breda, E, Artioli, G, Andreetta, C, Casanova, C, Ceccherini, R, Frassoldati, A, Salutari, V, Giolitto, S, Scambia, G, Lorusso D., Raspagliesi F., Ronzulli D., Valabrega G., Colombo N., Pisano C., Cassani C., Tognon G., Tamberi S., Mangili G., Mammoliti S., De Giorgi U., Greco F., Mosconi A. M., Breda E., Artioli G., Andreetta C., Casanova C., Ceccherini R., Frassoldati A., Salutari V., Giolitto S., and Scambia G.

Abstract

PURPOSELiterature evidence suggests that trabectedin monotherapy is effective in patients with recurrent ovarian cancer (OC) presenting BRCA mutation and/or BRCAness phenotype.METHODSA prospective, open-label, randomized phase III MITO-23 trial evaluated the activity and safety of trabectedin 1.3 mg/m2 given once every 3 weeks (arm A) in BRCA 1/2 mutation carriers or patients with BRCAness phenotype (ie, patients who responded to ≥two previous platinum-based treatments) with recurrent OC, primary peritoneal carcinoma, or fallopian tube cancer in comparison with physician's choice chemotherapy in the control arm (arm B; pegylated liposomal doxorubicin, topotecan, gemcitabine, once-weekly paclitaxel, or carboplatin). The primary end point was overall survival (OS) evaluated in the intention-to-treat population.RESULTSOverall, 244 patients from 21 MITO centers were randomly assigned (arm A = 122/arm B = 122). More than 70% of patients received ≥three previous chemotherapy lines and 35.7% had received a poly (ADP-ribose) polymerase inhibitor (PARPi) before enrollment. Median OS was not significantly different between the arms: arm A: 15.8 versus arm B: 17.9 months (P =.304). Median progression-free survival was 4.9 months in arm A versus 4.4 months in arm B (P =.897). Among 208 patients evaluable for efficacy, the objective response rate was 17.1% in arm A and 21.4% in arm B, with comparable median duration of response (5.62 v 5.66 months, respectively). No superior effect was observed for trabectedin in the prespecified subgroup analyses according to BRCA mutational status, chemotherapy type, and pretreatment with a PARPi and/or platinum-free interval. Trabectedin showed a higher frequency of grade ≥3 adverse events (AEs), serious AEs, and serious adverse drug reactions compared with control chemotherapy.CONCLUSIONTrabectedin did not improve median OS and showed a worse safety profile in comparison with physician's choice control chemotherapy.

Published
2024

12. Radical Nephroureterectomy Tetrafecta: A Proposal Reporting Surgical Strategy Quality at Surgery

Author

Soria, Francesco, Pradere, B., Hurle, R., D'Andrea, D., Albisinni, S., Diamand, R., Laukhtina, E., Di Trapani, E., Aziz, A., Krajewski, W., Teoh, J.Y., Mari, A., Moschini, M., Chiancone, F., Autorino, R., Porreca, A., Marchioni, M., Liguori, G., Lucarelli, G., Busetto, G.M., Foschi, N., Antonelli, A., Bove, P., Russo, G.I., Crisan, N., Borghesi, M., Boeri, L., Veccia, A., Greco, F., Longo, N., De Cobelli, O., Shariat, S.F., Gontero, P., and Ferro, M.

Published
2022
Full Text
View/download PDF

13. Pricing Cyber Insurance: A Geospatial Statistical Approach.

Author

Ballestra, L. V., D'Amato, V., Fersini, P., Forte, S., and Greco, F.

Subjects
GAUSSIAN Markov random fields, INSURANCE companies, INSURANCE policies, MARKOV processes, GEOSPATIAL data, DATA security insurance
Abstract

Cyberspace is a dynamic ecosystem consisting of interconnected data, devices, and individuals, with multiple network layers comprising identifiable nodes. Location‐based information can significantly improve cyber resilience decision‐making and facilitate the development of innovative cyber risk pricing tools. This article is based on a methodology that uses company geospatial data to accurately estimate the number of expected losses arising from cyberattacks. Our approach aims to build and compare statistical spatial models that allow pricing cyber policies more effectively than traditional non‐spatial methods by incorporating all available data. By accounting for spatial dependence, we can assess the risk of data breaches and contribute to the design of more efficient cyber risk policies for the insurance market. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Comparison between 14G and 18G needle in performing transperineal prostate biopsies: Preliminary results on sample quality, patient discomforts and complications rates from a non-inferiority randomized trial

Author

Panunzio, A., primary, Tafuri, A., additional, Rizzo, M., additional, Fasano, C., additional, Zacheo, F., additional, Orlando, R., additional, Mancini, A., additional, De Carlo, F., additional, Di Cosmo, F., additional, Luperto, E., additional, Greco, F., additional, Giordano, L., additional, Maglietta, A., additional, and Pagliarulo, V., additional

Published
2024
Full Text
View/download PDF

18. I prodotti d’investimento assicurativo (c.d. Ibips): tra nuove categorie e vecchi problemi

Author

di Gorgoni M. (cur.) Greco F. (cur.), Montani, Veronica, v. montani (ORCID:0000-0002-6988-6773), di Gorgoni M. (cur.) Greco F. (cur.), Montani, Veronica, and v. montani (ORCID:0000-0002-6988-6773)

Abstract

il contributo affronta il tema dei prodotti d’investimento assicurativo, analizzandone la disciplina interna e i problemi di compatibilità con il perimetro del diritto assicurativo

Published
2024

19. L'assicurazione del patrimonio e di cose

Author

Pellerino, G, Marchetti P - Bray E, De Poli, M, Vito Russo, T, Murgo, C, Chironi, M, Zurlo, A, Bosetti, F, Gagliardi, M, Greco, G G, Dito, D A, Albanese, L, Pardini, S, Iorio, G, Onnis Cugia, F, Greco, F, Bugli, A - Travaglino G P, Montani V, Marino R, Marilena Gorgoni e Fernando Greco, Pellerino, G, Marchetti P - Bray E, De Poli, M, Vito Russo, T, Murgo, C, Chironi, M, Zurlo, A, Bosetti, F, Gagliardi, M, Greco, G G, Dito, D A, Albanese, L, Pardini, S, Iorio, G, Onnis Cugia, F, Greco, F, Bugli, A - Travaglino G P, Montani V, Marino R, and Marilena Gorgoni e Fernando Greco

Abstract

Il contributo intende esaminare le principali problematiche riguardanti l'assicurazione del patrimonio e di cose. Si ha riguardo, in particolare: all'assicurazione sulla casa, all'assicurazione dell'auto e di altri veicoli; all'assicurazione di macchinari industriali; all'assicurazione delle opere d'arte; all'assicurazione per eventi che incidono sulla "capacità reddituale" dell'assicurato

Published
2024

20. Role of micronutrients in the symptoms of fibromyalgia: a review of the literature and analysis of an Italian female sample.

Author

TARSITANO, M. G., DOLCINI, G., PANDOZZI, C., GRECO, F., IANNUNCELLI, C., CONTE, C., GIANNETTA, E., and DI FRANCO, M.

Abstract

OBJECTIVE: Fibromyalgia (FM) is a multifactorial disease characterized principally by chronic, widespread pain impairing a patient's quality of life. The management of FM requires a multidisciplinary approach that combines pharmacological and non-pharmacological strategies. Growing evidence suggests a potential beneficial role of micronutrients such as minerals and vitamins. Overall, the role of these supplements remains controversial, but clinical trials on vitamin D, vitamin B12, magnesium, and iron supplementation seem to provide promising results. The aim of this study was to investigate their role in an Italian female sample. SUBJECTS AND METHODS: An exploratory cross-sectional study was done to assess the association of selected micronutrients with symptoms of FM by using the Fibromyalgia Impact Questionnaire (FIQ) in twenty consecutive female patients with FM. A literature review was also conducted. RESULTS: FIQ results revealed that vitamin D and magnesium deficiency appear to play a role in FM symptoms, mainly in physical function and stiffness. From the literature review, only two studies investigating the role of micronutrients in FM were retrieved. CONCLUSIONS: Screening for micronutrient deficiencies in FM patients and supplementing them when levels are low might help counteract FM symptoms. [ABSTRACT FROM AUTHOR]

Published
2024

25. Robotic vs laparoscopic approach for single anastomosis duodenal-ileal bypass with sleeve gastrectomy: a propensity score matching analysis

Author

Pennestri, F., Sessa, L., Prioli, F., Gallucci, P., Ciccoritti, Luigi, Greco, F., De Crea, Carmela, Raffaelli, Marco, Pennestri F., Sessa L., Prioli F., Gallucci P., Ciccoritti L., Greco F., De Crea C. (ORCID:0000-0002-7303-9657), Raffaelli M. (ORCID:0000-0002-1259-2491), Pennestri, F., Sessa, L., Prioli, F., Gallucci, P., Ciccoritti, Luigi, Greco, F., De Crea, Carmela, Raffaelli, Marco, Pennestri F., Sessa L., Prioli F., Gallucci P., Ciccoritti L., Greco F., De Crea C. (ORCID:0000-0002-7303-9657), and Raffaelli M. (ORCID:0000-0002-1259-2491)

Abstract

Biliopancreatic diversion with duodenal switch and single anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S) are technically demanding hypo-absorptive bariatric procedures. They are often indicated in superobese patients (BMI ≥ 50 kg/m2), as robotic platform could improve ergonomics against a thick abdominal wall, preventing bending of instruments and simplifying hand-sewn anastomoses. We aimed to report our experience with robotic SADI-S (R-group) and to compare outcomes with the laparoscopic (L-group) approach. Among 2143 patients who underwent bariatric procedures at our institution between July 2016 and June 2021, 116 (5.4%) consenting patients were scheduled for SADI-S as primary or revisional procedure: 94 L-group, 22 R-group. R-group and L-group patients were matched using PSM analysis to overcome patients selection bias. Postoperative complications, operative time (OT), post-operative stay (POS) and follow-up data were compared. After PSM, 44 patients (22 patients for each group) were compared (Chi-square 0.317, p = 0.985). Median age, gender, median BMI, preoperative rates of comorbidities, previous abdominal bariatric and non-bariatric surgeries and type of surgical procedures (SADI-S/SADI) were comparable. Median OT was shorter in the L-group (130 Vs 191 min, p < 0.001). 30-days’ re-operative complications and late complications rates were comparable. At 25-months’ mean follow-up, the median Percentage Excess Weight Loss (72%) was comparable between the groups (p = 0.989). L-group and R-group were comparable in terms of re-operative complication rate and short-term outcomes. The robotic platform may increase the rate of single step procedure in challenging cases. Larger studies with longer follow-up and cost-analysis are necessary to draw definitive conclusions.

Published
2023

26. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Author

Di Lisa, F, Krasniqi, E, Pizzuti, L, Barba, M, Cannita, K, De Giorgi, U, Borella, F, Foglietta, J, Cariello, A, Ferro, A, Picardo, E, Mitidieri, M, Sini, V, Stani, S, Tonini, G, Santini, D, La Verde, N, Gambaro, A, Grassadonia, A, Tinari, N, Garrone, O, Sarobba, G, Livi, L, Meattini, I, D'Auria, G, Vergati, M, Gamucci, T, Pistelli, M, Berardi, R, Risi, E, Giotta, F, Lorusso, V, Rinaldi, L, Artale, S, Cazzaniga, M, Zustovich, F, Cappuzzo, F, Landi, L, Torrisi, R, Scagnoli, S, Botticelli, A, Michelotti, A, Fratini, B, Saltarelli, R, Paris, I, Muratore, M, Cassano, A, Gianni, L, Gaspari, V, Veltri, E, Zoratto, F, Fiorio, E, Fabbri, M, Mazzotta, M, Ruggeri, E, Pedersini, R, Valerio, M, Filomeno, L, Minelli, M, Scavina, P, Raffaele, M, Astone, A, De Vita, R, Pozzi, M, Riccardi, F, Greco, F, Moscetti, L, Giordano, M, Maugeri-Sacca, M, Zennaro, A, Botti, C, Pelle, F, Cappelli, S, Cavicchi, F, Vizza, E, Sanguineti, G, Tomao, F, Cortesi, E, Marchetti, P, Tomao, S, Speranza, I, Sperduti, I, Ciliberto, G, Vici, P, Di Lisa F. S., Krasniqi E., Pizzuti L., Barba M., Cannita K., De Giorgi U., Borella F., Foglietta J., Cariello A., Ferro A., Picardo E., Mitidieri M., Sini V., Stani S., Tonini G., Santini D., La Verde N., Gambaro A. R., Grassadonia A., Tinari N., Garrone O., Sarobba G., Livi L., Meattini I., D'Auria G., Vergati M., Gamucci T., Pistelli M., Berardi R., Risi E., Giotta F., Lorusso V., Rinaldi L., Artale S., Cazzaniga M. E., Zustovich F., Cappuzzo F., Landi L., Torrisi R., Scagnoli S., Botticelli A., Michelotti A., Fratini B., Saltarelli R., Paris I., Muratore M., Cassano A., Gianni L., Gaspari V., Veltri E. M., Zoratto F., Fiorio E., Fabbri M. A., Mazzotta M., Ruggeri E. M., Pedersini R., Valerio M. R., Filomeno L., Minelli M., Scavina P., Raffaele M., Astone A., De Vita R., Pozzi M., Riccardi F., Greco F., Moscetti L., Giordano M., Maugeri-Sacca M., Zennaro A., Botti C., Pelle F., Cappelli S., Cavicchi F., Vizza E., Sanguineti G., Tomao F., Cortesi E., Marchetti P., Tomao S., Speranza I., Sperduti I., Ciliberto G., Vici P., Di Lisa, F, Krasniqi, E, Pizzuti, L, Barba, M, Cannita, K, De Giorgi, U, Borella, F, Foglietta, J, Cariello, A, Ferro, A, Picardo, E, Mitidieri, M, Sini, V, Stani, S, Tonini, G, Santini, D, La Verde, N, Gambaro, A, Grassadonia, A, Tinari, N, Garrone, O, Sarobba, G, Livi, L, Meattini, I, D'Auria, G, Vergati, M, Gamucci, T, Pistelli, M, Berardi, R, Risi, E, Giotta, F, Lorusso, V, Rinaldi, L, Artale, S, Cazzaniga, M, Zustovich, F, Cappuzzo, F, Landi, L, Torrisi, R, Scagnoli, S, Botticelli, A, Michelotti, A, Fratini, B, Saltarelli, R, Paris, I, Muratore, M, Cassano, A, Gianni, L, Gaspari, V, Veltri, E, Zoratto, F, Fiorio, E, Fabbri, M, Mazzotta, M, Ruggeri, E, Pedersini, R, Valerio, M, Filomeno, L, Minelli, M, Scavina, P, Raffaele, M, Astone, A, De Vita, R, Pozzi, M, Riccardi, F, Greco, F, Moscetti, L, Giordano, M, Maugeri-Sacca, M, Zennaro, A, Botti, C, Pelle, F, Cappelli, S, Cavicchi, F, Vizza, E, Sanguineti, G, Tomao, F, Cortesi, E, Marchetti, P, Tomao, S, Speranza, I, Sperduti, I, Ciliberto, G, Vici, P, Di Lisa F. S., Krasniqi E., Pizzuti L., Barba M., Cannita K., De Giorgi U., Borella F., Foglietta J., Cariello A., Ferro A., Picardo E., Mitidieri M., Sini V., Stani S., Tonini G., Santini D., La Verde N., Gambaro A. R., Grassadonia A., Tinari N., Garrone O., Sarobba G., Livi L., Meattini I., D'Auria G., Vergati M., Gamucci T., Pistelli M., Berardi R., Risi E., Giotta F., Lorusso V., Rinaldi L., Artale S., Cazzaniga M. E., Zustovich F., Cappuzzo F., Landi L., Torrisi R., Scagnoli S., Botticelli A., Michelotti A., Fratini B., Saltarelli R., Paris I., Muratore M., Cassano A., Gianni L., Gaspari V., Veltri E. M., Zoratto F., Fiorio E., Fabbri M. A., Mazzotta M., Ruggeri E. M., Pedersini R., Valerio M. R., Filomeno L., Minelli M., Scavina P., Raffaele M., Astone A., De Vita R., Pozzi M., Riccardi F., Greco F., Moscetti L., Giordano M., Maugeri-Sacca M., Zennaro A., Botti C., Pelle F., Cappelli S., Cavicchi F., Vizza E., Sanguineti G., Tomao F., Cortesi E., Marchetti P., Tomao S., Speranza I., Sperduti I., Ciliberto G., and Vici P.

Abstract

Background: In triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine, based on the results of the randomized CREATE-X study, carried out in Asian patients and including a small subset of triple negative tumors. Thus far, evidence on Caucasian patients is limited, and no real-world data are available. Methods: We carried out a multicenter, observational study, involving 44 oncologic centres. Triple negative breast cancer patients with residual disease, treated with adjuvant capecitabine from January 2017 through June 2021, were recruited. We primarily focused on treatment tolerability, with toxicity being reported as potential cause of treatment discontinuation. Secondarily, we assessed effectiveness in the overall study population and in a subset having a minimum follow-up of 2 years. Results: Overall, 270 patients were retrospectively identified. The 50.4% of the patients had residual node positive disease, 7.8% and 81.9% had large or G3 residual tumor, respectively, and 80.4% a Ki-67 >20%. Toxicity-related treatment discontinuation was observed only in 10.4% of the patients. In the whole population, at a median follow-up of 15 months, 2-year disease-free survival was 62%, 2 and 3-year overall survival 84.0% and 76.2%, respectively. In 129 patients with a median follow-up of 25 months, 2-year disease-free survival was 43.4%, 2 and 3-year overall survival 78.0% and 70.8%, respectively. Six or more cycles of capecitabine were associated with more favourable outcomes compared with less than six cycles. Conclusion: The CaRe study shows an unexpectedly good tolerance of adjuvant capecitabine in a real-world setting, although effectiveness appears to be lower than that observed in the CREATE-X study. Methodological differences between the two studies impose significant limits to comparability concerning ef

Published
2023

39. Revisional Surgery After One Anastomosis/Minigastric Bypass: an Italian Multi-institutional Survey

Author

Musella M., Vitiello A., Susa A., Greco F., De Luca M., Manno E., Olmi S., Raffaelli M., Lucchese M., Carandina S., Foletto M., Pizza F., Bardi U., Navarra G., Schettino A. M., Gentileschi P., Sarro G., Chiappetta S., Tirone A., Berardi G., Velotti N., Foschi D., Zappa M., Piazza L., Bagaglini G., Benavoli D., Belluzzi A., Callari C., Giusti M., Facchiano E., Licari L., Iovino G., Piatto G., Stanzione F., Uccelli M., Veroux G., Voglino C., Musella, M., Vitiello, A., Susa, A., Greco, F., De Luca, M., Manno, E., Olmi, S., Raffaelli, M., Lucchese, M., Carandina, S., Foletto, M., Pizza, F., Bardi, U., Navarra, G., Schettino, A. M., Gentileschi, P., Sarro, G., Chiappetta, S., Tirone, A., Berardi, G., Velotti, N., Foschi, D., Zappa, M., Piazza, L., Bagaglini, G., Benavoli, D., Belluzzi, A., Callari, C., Giusti, M., Facchiano, E., Licari, L., Iovino, G., Piatto, G., Stanzione, F., Uccelli, M., Veroux, G., Voglino, C., Musella, Mario, Vitiello, Antonio, Susa, Antonio, Greco, Francesco, De Luca, Maurizio, Manno, Emilio, Olmi, Stefano, Raffaelli, Marco, Lucchese, Marcello, Carandina, Sergio, Foletto, Mirto, Pizza, Francesco, Bardi, Ugo, Navarra, Giuseppe, Schettino, Angelo Michele, Gentileschi, Paolo, Sarro, Giuliano, Chiappetta, Sonja, Tirone, Andrea, Berardi, Giovanna, Velotti, Nunzio, Foschi, Diego, Zappa, Marco, and Piazza, Luigi

Subjects
Gastric Fistula, Reoperation, One anastomosis gastric bypass, Nutrition and Dietetics, Complications, Endocrinology, Diabetes and Metabolism, Mini gastric bypa, Original Contributions, Revisional surgery, Gastric Bypass, Mini gastric bypass, OAGB/MGB, Obesity, Morbid, One anastomosis gastric bypa, Surveys and Questionnaires, Weight Loss, Humans, Surgery, Complication, Retrospective Studies
Abstract

Background Efficacy and safety of OAGB/MGB (one anastomosis/mini gastric bypass) have been well documented both as primary and as revisional procedures. However, even after OAGB/MGB, revisional surgery is unavoidable in patients with surgical complications or insufficient weight loss. Methods A questionnaire asking for the total number and demographics of primary and revisional OAGB/MGBs performed between January 2006 and July 2020 was e-mailed to all S.I.C. OB centres of excellence (annual caseload > 100; 5-year follow-up > 50%). Each bariatric centre was asked to provide gender, age, preoperative body mass index (BMI) and obesity-related comorbidities, previous history of abdominal or bariatric surgery, indication for surgical revision of OAGB/MGB, type of revisional procedure, pre- and post-revisional BMI, peri- and post-operative complications, last follow-up (FU). Results Twenty-three bariatric centres (54.8%) responded to our survey reporting a total number of 8676 primary OAGB/MGBS and a follow-up of 62.42 ± 52.22 months. A total of 181 (2.08%) patients underwent revisional surgery: 82 (0.94%) were suffering from intractable DGER (duodeno-gastric-esophageal reflux), 42 (0.48%) were reoperated for weight regain, 16 (0.18%) had excessive weight loss and malnutrition, 12 (0.13%) had a marginal ulcer perforation, 10 (0.11%) had a gastro-gastric fistula, 20 (0.23%) had other causes of revision. Roux-en-Y gastric bypass (RYGB) was the most performed revisional procedure (109; 54%), followed by bilio-pancreatic limb elongation (19; 9.4%) and normal anatomy restoration (19; 9.4%). Conclusions Our findings demonstrate that there is acceptable revisional rate after OAGB/MGB and conversion to RYGB represents the most frequent choice. Graphical abstract

Published
2022

40. Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes.

Author

Lembo, E, Russo, Mf, Verrastro, O, Anello, D, Angelini, G, Iaconelli, A, Guidone, C, Stefanizzi, G, Ciccoritti, L, Greco, F, Sessa, L, Riccardi, L, Pompili, M, Raffaelli, M, Vecchio, Fm, Bornstein, Sr, Mingrone, G, Gastaldelli, A, Capristo, E., Lembo E, Russo MF, Verrastro O, Anello D, Angelini G, Iaconelli A, Guidone C, Stefanizzi G, Ciccoritti L, Greco F, Sessa L, Riccardi L, Pompili M (ORCID:0000-0001-6699-7980), Raffaelli M (ORCID:0000-0002-1259-2491), Vecchio FM (ORCID:0000-0002-9197-2264), Bornstein SR, Mingrone G (ORCID:0000-0003-2021-528X), Gastaldelli A, Capristo E. (ORCID:0000-0002-5753-3495), Lembo, E, Russo, Mf, Verrastro, O, Anello, D, Angelini, G, Iaconelli, A, Guidone, C, Stefanizzi, G, Ciccoritti, L, Greco, F, Sessa, L, Riccardi, L, Pompili, M, Raffaelli, M, Vecchio, Fm, Bornstein, Sr, Mingrone, G, Gastaldelli, A, Capristo, E., Lembo E, Russo MF, Verrastro O, Anello D, Angelini G, Iaconelli A, Guidone C, Stefanizzi G, Ciccoritti L, Greco F, Sessa L, Riccardi L, Pompili M (ORCID:0000-0001-6699-7980), Raffaelli M (ORCID:0000-0002-1259-2491), Vecchio FM (ORCID:0000-0002-9197-2264), Bornstein SR, Mingrone G (ORCID:0000-0003-2021-528X), Gastaldelli A, and Capristo E. (ORCID:0000-0002-5753-3495)

Abstract

Aim: To investigate the prevalence of biopsy-proven non-alcoholic steatohepatitis (NASH) in a cohort of patients with morbid obesity and with or without type 2 diabetes (T2D) and to find non-invasive predictors of NASH severity. Methods: We evaluated a cohort of 412 subjects (age 19-67 years, body mass index-BMI: 44.98 kg/m2), who underwent fine-needle liver biopsy during bariatric surgery. Thirty-six percent of the subjects were affected by T2D. Liver biopsies were classified according to the Kleiner's NAFLD Activity Score (NAS). NAFLD Fibrosis Score (NFS), AST/ALT ratio, AST to Platelet ratio (APRI), fibrosis-4 score (FIB4) were calculated. A neural network analysis (NNA) was run to predict NASH severity. Results: The prevalence of biopsy-proven NASH was 63% and 78% in subjects with obesity and without or with T2D, respectively. T2D doubled the risk of NASH [OR 2.079 (95% IC=1.31-3.29)]. The prevalence of NAFL increased with the increase of BMI, while there was an inverse correlation between BMI and NASH (r=-0.145 p=0.003). Only mild liver fibrosis was observed. HOMA-IR was positively associated with hepatocyte ballooning (r=0.208, p<0.0001) and fibrosis (r=0.159, p=0.008). The NNA highlighted a specificity of 77.3% using HDL-cholesterol, BMI, and HOMA-IR as main determinants of NASH. Conclusions: Our data show a higher prevalence of NASH in patients with morbid obesity than reported in the literature and the pivotal role of T2D among the risk factors for NASH development. However, the inverse correlation observed between BMI and biopsy-proven NASH suggests that over a certain threshold adiposity can be somewhat protective against liver damage. Our model predicts NASH presence with high specificity, thus helping identifying subjects who should promptly undergo liver biopsy.

Published
2022

41. High Prevalence of Mental Health Disorders in Adolescents and Youth Living with HIV: An Observational Study from Eight Health Services in Sofala Province, Mozambique

Author

Di Gennaro, F, Marotta, C, Ramirez, L, Cardoso, H, Alamo, C, Cinturao, V, Bavaro, D, Mahotas, D, Lazzari, M, Fernando, C, Chimundi, N, Atzori, A, Chaguruca, I, Tognon, F, Guambe Dos Anjos, H, De Meneghi, G, Tribie, M, Del Greco, F, Namarime, E, Occa, E, Putoto, G, Pozniak, A, Saracino, A, Di Gennaro F., Marotta C., Ramirez L., Cardoso H., Alamo C., Cinturao V., Bavaro D. F., Mahotas D. C., Lazzari M., Fernando C., Chimundi N., Atzori A., Chaguruca I., Tognon F., Guambe Dos Anjos H., De Meneghi G., Tribie M., Del Greco F., Namarime E., Occa E., Putoto G., Pozniak A., Saracino A., Di Gennaro, F, Marotta, C, Ramirez, L, Cardoso, H, Alamo, C, Cinturao, V, Bavaro, D, Mahotas, D, Lazzari, M, Fernando, C, Chimundi, N, Atzori, A, Chaguruca, I, Tognon, F, Guambe Dos Anjos, H, De Meneghi, G, Tribie, M, Del Greco, F, Namarime, E, Occa, E, Putoto, G, Pozniak, A, Saracino, A, Di Gennaro F., Marotta C., Ramirez L., Cardoso H., Alamo C., Cinturao V., Bavaro D. F., Mahotas D. C., Lazzari M., Fernando C., Chimundi N., Atzori A., Chaguruca I., Tognon F., Guambe Dos Anjos H., De Meneghi G., Tribie M., Del Greco F., Namarime E., Occa E., Putoto G., Pozniak A., and Saracino A.

Abstract

Adolescent mental health (MH) is a significant global health concern, which is extremely relevant when referring to adolescents and youth living with HIV (AYHIV). In Mozambique, ∼52% of the population is [removed] 10 for women, [adjusting odds ratio (AOR): 1.46, 95% confidence interval (CI): 1.01-2.10], for workers (AOR: 2.18, 95% CI: 1.12-4.23) and people living with HIV (AOR: 1.78, 95% CI: 1.25-2.54). Higher values of CAGE (≥2) and PTSD (≥3) seemed to be associated only with HIV-positive status (AOR: 4.87, 95% CI: 3.72-6.38 and AOR: 1.73, 95% CI: 1.28-237). These data further reinforce the urgent need for a global health policy action with focused intervention on MH in AYHIV patients.

Published
2022

42. Whole Exome Sequencing Enhanced Imputation Identifies 85 Metabolite Associations in the Alpine CHRIS Cohort

Author

Konig, E, Rainer, J, Hernandes, V, Paglia, G, Del Greco, F, Bottigliengo, D, Yin, X, Chan, L, Teumer, A, Pramstaller, P, Locke, A, Fuchsberger, C, Konig E., Rainer J., Hernandes V. V., Paglia G., Del Greco F. M., Bottigliengo D., Yin X., Chan L. S., Teumer A., Pramstaller P. P., Locke A. E., Fuchsberger C., Konig, E, Rainer, J, Hernandes, V, Paglia, G, Del Greco, F, Bottigliengo, D, Yin, X, Chan, L, Teumer, A, Pramstaller, P, Locke, A, Fuchsberger, C, Konig E., Rainer J., Hernandes V. V., Paglia G., Del Greco F. M., Bottigliengo D., Yin X., Chan L. S., Teumer A., Pramstaller P. P., Locke A. E., and Fuchsberger C.

Abstract

Metabolites are intermediates or end products of biochemical processes involved in both health and disease. Here, we take advantage of the well-characterized Cooperative Health Research in South Tyrol (CHRIS) study to perform an exome-wide association study (ExWAS) on absolute concentrations of 175 metabolites in 3294 individuals. To increase power, we imputed the identified variants into an additional 2211 genotyped individuals of CHRIS. In the resulting dataset of 5505 in-dividuals, we identified 85 single-variant genetic associations, of which 39 have not been reported previously. Fifteen associations emerged at ten variants with >5-fold enrichment in CHRIS compared to non-Finnish Europeans reported in the gnomAD database. For example, the CHRIS-enriched ETFDH stop gain variant p.Trp286Ter (rs1235904433-hexanoylcarnitine) and the MCCC2 stop lost variant p.Ter564GlnextTer3 (rs751970792-carnitine) have been found in patients with glutaric acidemia type II and 3-methylcrotonylglycinuria, respectively, but the loci have not been associated with the respective metabolites in a genome-wide association study (GWAS) previously. We further identified three gene-trait associations, where multiple rare variants contribute to the signal. These results not only provide further evidence for previously described associations, but also describe novel genes and mechanisms for diseases and disease-related traits.

Published
2022

43. Flow of Dry Grains Inside Rotating Drums

Author

De Monaco, G., Greco, F., Maffettone, P. L., Proulx, Tom, Series editor, Qi, H. Jerry, editor, Antoun, Bonnie, editor, Hall, Richard, editor, Lu, Hongbing, editor, Arzoumanidis, Alex, editor, Silberstein, Meredith, editor, Furmanski, Jevan, editor, Amirkhizi, Alireza, editor, and Gonzalez-Gutierrez, Joamin, editor

Published
2015
Full Text
View/download PDF

47. Data from A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

Author

Cohen, Roger B., primary, Jones, Suzanne F., primary, Aggarwal, Charu, primary, von Mehren, Margaret, primary, Cheng, Jonathan, primary, Spigel, David R., primary, Greco, F. Anthony, primary, Mariani, Mariangela, primary, Rocchetti, Maurizio, primary, Ceruti, Roberta, primary, Comis, Silvia, primary, Laffranchi, Bernard, primary, Moll, Jurgen, primary, and Burris, Howard A., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Data from Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary

Author

Raghav, Kanwal, primary, Hwang, Hyunsoo, primary, Jácome, Alexandre A., primary, Bhang, Eric, primary, Willett, Anneleis, primary, Huey, Ryan W., primary, Dhillon, Nishat P., primary, Modha, Jignesh, primary, Smaglo, Brandon, primary, Matamoros, Aurelio, primary, Estrella, Jeannelyn S., primary, Jao, Justin, primary, Overman, Michael J., primary, Wang, Xuemei, primary, Greco, F. Anthony, primary, Loree, Jonathan M., primary, and Varadhachary, Gauri R., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Data from A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

Author

Cohen, Roger B., primary, Jones, Suzanne F., primary, Aggarwal, Charu, primary, von Mehren, Margaret, primary, Cheng, Jonathan, primary, Spigel, David R., primary, Greco, F. Anthony, primary, Mariani, Mariangela, primary, Rocchetti, Maurizio, primary, Ceruti, Roberta, primary, Comis, Silvia, primary, Laffranchi, Bernard, primary, Moll, Jurgen, primary, and Burris, Howard A., primary

Published
2023
Full Text
View/download PDF

50. SICOB-endorsed national Delphi consensus on obesity treatment optimization: focus on diagnosis, pre-operative management, and weight regain/insufficient weight loss approach

Author

Zappa, M. A., Iossa, A., Busetto, L., Chiappetta, S., Greco, F., Lucchese, M., Micanti, F., Mingrone, Geltrude, Navarra, G., Raffaelli, Marco, Altorio, S. F., Angrisani, L., Arcudi, C., Bellini, F., Bernante, P., Berta, R., Capristo, Esmeralda, Carbonelli, M. G., Casella, G., Casella, J. M., Castagneto Gissey, L., Cerbone, M. R., Ciampaglia, F., Ciccoritti, Luigi, Contine, A., Curro, G., D'Alessio, R., De Palma, M., Delle Piane, D., Di Benedetto, N., Di Lorenzo, N., Fantola, G., Farnaz, R., Foletto, M., Forestieri, P., Frittitta, L., Galfrascoli, E., Gentileschi, P., Giardiello, C., Giustacchini, Piero, Giusti, M. P., Grandone, I., Guidone, Caterina, Iaconelli, Amerigo, Lembo, Erminia, Leanza, S., Lezoche, G., Lunardi, C., Martines, G., Marzano, B., Paone, E., Papadia, F. S., Perrone, F., Piazza, L., Pilone, V., Pizzi, P., Rice, M., Rizzi, A., Santini, F., Sarro, G., Schettino, A., Tartaglia, N., Toppino, Piero Maria, Usai, Alessandro, De Luca, Marianna, Mingrone G. (ORCID:0000-0003-2021-528X), Raffaelli M. (ORCID:0000-0002-1259-2491), Capristo E. (ORCID:0000-0002-5753-3495), Ciccoritti L., Giustacchini P., Guidone C., Iaconelli A., Lembo E., Toppino M., Usai A., De Luca M. (ORCID:0000-0002-9996-6563), Zappa, M. A., Iossa, A., Busetto, L., Chiappetta, S., Greco, F., Lucchese, M., Micanti, F., Mingrone, Geltrude, Navarra, G., Raffaelli, Marco, Altorio, S. F., Angrisani, L., Arcudi, C., Bellini, F., Bernante, P., Berta, R., Capristo, Esmeralda, Carbonelli, M. G., Casella, G., Casella, J. M., Castagneto Gissey, L., Cerbone, M. R., Ciampaglia, F., Ciccoritti, Luigi, Contine, A., Curro, G., D'Alessio, R., De Palma, M., Delle Piane, D., Di Benedetto, N., Di Lorenzo, N., Fantola, G., Farnaz, R., Foletto, M., Forestieri, P., Frittitta, L., Galfrascoli, E., Gentileschi, P., Giardiello, C., Giustacchini, Piero, Giusti, M. P., Grandone, I., Guidone, Caterina, Iaconelli, Amerigo, Lembo, Erminia, Leanza, S., Lezoche, G., Lunardi, C., Martines, G., Marzano, B., Paone, E., Papadia, F. S., Perrone, F., Piazza, L., Pilone, V., Pizzi, P., Rice, M., Rizzi, A., Santini, F., Sarro, G., Schettino, A., Tartaglia, N., Toppino, Piero Maria, Usai, Alessandro, De Luca, Marianna, Mingrone G. (ORCID:0000-0003-2021-528X), Raffaelli M. (ORCID:0000-0002-1259-2491), Capristo E. (ORCID:0000-0002-5753-3495), Ciccoritti L., Giustacchini P., Guidone C., Iaconelli A., Lembo E., Toppino M., Usai A., and De Luca M. (ORCID:0000-0002-9996-6563)

Abstract

Purpose: Overweight and obesity affects 60% of adults causing more than 1.2 million deaths across world every year. Fight against involved different specialist figures and multiple are the approved weapons. Aim of the present survey endorsed by the Italian Society of Bariatric Surgery (SICOB) is to reach a national consensus on obesity treatment optimization through a Delphi process. Methods: Eleven key opinion leaders (KOLs) identified 22 statements with a major need of clarification and debate. The explored pathways were: (1) Management of patient candidate to bariatric/metabolic surgery (BMS); (2) Management of patient not eligible for BMS; (3) Management of patient with short-term (2 years) weight regain (WR) or insufficient weight loss (IWL); (4) Management of the patient with medium-term (5 years) WR; and (5) Association between drugs and BMS as WR prevention. The questionnaire was distributed to 65 national experts via an online platform with anonymized results. Results: 54 out of 65 invited panelists (83%) respond. Positive consensus was reached for 18/22 statements (82%); while, negative consensus (s20.4; s21.5) and no consensus (s11.5, s17) were reached for 2 statements, respectively (9%). Conclusion: The Delphi results underline the importance of first-line interdisciplinary management, with large pre-treatment examination, and establish a common opinion on how to properly manage post-operative IWL/WR. Level of evidence V: Report of expert committees.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results